Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications. Additionally, Orphan Drug Designation of the product provides the developers seven years of US market exclusivity and independent from the Company's intellectual property protection.
"Receiving the Orphan Drug Designation for s-KL-AAV.myo for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule.
ALS is sometimes referred to as Lou Gehrig's disease. Lou Gehrig, who played for the New York Yankees for 17 years in the 1920s and 1930s, stunned players and fans by retiring from baseball at the age of 36 after being diagnosed with ALS. Prior to this diagnosis, Gehrig played in a record-breaking 2,130 consecutive games, was referred to as the "Iron Horse," and was considered one of the greatest baseball players of all time. Less than two years later, at the age of 37, Gehrig died of complications from ALS. ALS is also referred to as Motor Neuron Disease in the UK and elsewhere. ALS is considered a rare disease and affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year.
Klotho Neurosciences will have completed "proof of concept" studies in two animal models of human ALS and the Company is currently initiating manufacturing of the ALS-targeted product candidate, followed by meetings with the U.S. FDA and EMA in Europe to concur with the development path going forward.
KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority.
About Klotho Neurosciences, Inc.Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, please visit the company's website at www.klothoneuro.com.
Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFOir@klothoneuro.com
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-inc-granted-fda-orphan-drug-designation-for-klto-202-for-treatment-of-amyotrophic-lateral-sclerosis-als-or-lou-gehrigs-disease-302501830.html
SOURCE Klotho Neurosciences, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
Hybrid, Multicloud Strategies Gain Traction in U.K.
LONDON--(BUSINESS WIRE)--Enterprises across the U.K. are rapidly modernizing their cloud infrastructures, motivated by a surge in AI and ML workloads that demand scalable and secure cloud solutions, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. U.K. enterprises are moving to hybrid and multicloud platforms to support AI and ML workloads and safeguard sensitive data. These platforms are crucial for protecting organizations against ransomware and malware threats and for achieving cost efficiency. The 2025 ISG Provider Lens ® Private/Hybrid Cloud — Data Center Services report for the U.K. finds an upward trend in the adoption of hybrid and multicloud infrastructure models, with significant growth anticipated within the next three years. Performance, data sovereignty, security and regulatory pressures are the primary drivers of this growth. Hybrid cloud is now the preferred model for many U.K. enterprises, because it lets organizations align workloads with appropriate environments and improve data protection. 'U.K. enterprises are actively transitioning toward hybrid and multicloud platforms to support AI and ML workloads and safeguard sensitive data,' said Anthony Drake, partner at ISG. 'These flexible platforms are crucial for protecting organizations against ransomware and malware threats and for achieving cost efficiency.' Enterprises in the U.K. are using hybrid clouds to enhance security with private cloud resources while simultaneously gaining cost savings and flexible scalability from public clouds, ISG says. Increasingly, they are deploying real-time monitoring and ML within private clouds to strengthen data protection, particularly in highly regulated sectors such as healthcare and finance. As organizations embrace cloud environments, they are engaged in large-scale migration of business applications. Most organizations in the U.K. have migrated applications between environments to improve efficiency, capacity, security and innovation, the report says. Companies are optimizing on-premises and private cloud environments by integrating graphics processing units (GPUs) and expanding storage capacities. This approach eases handling of AI and analytical tasks while improving efficiency and resource utilization. Small and midsize enterprises (SMEs) in the U.K. are focused on developing customized cloud solutions to meet industry-specific demands. The uptake of modular data center designs is also on the rise, owing to their low total cost of ownership and accelerated deployment capabilities, ISG says. The U.K. government's designation of data centers as critical infrastructure, coupled with streamlined planning laws, facilitates new data center projects and reinforces a national focus on data protection. The capacity of U.K. data centers is expected to increase twofold by 2028, mainly driven by growing demand for generative AI (GenAI), cloud computing and government-supported infrastructure. 'The U.K.'s cloud market is undergoing rapid transformation, with organizations seeking agility through tailored solutions and modular data center designs,' said Meenakshi Srivastava, lead analyst, ISG Provider Lens Research, and lead author of the report. 'By 2025, 75 percent of enterprise data will be processed outside traditional data centers or cloud environments, indicating a shift in data management practices.' The report also explores other trends related to private/hybrid cloud and data center services in the U.K., including an increased emphasis on sustainability and the integration of agentic AI into hybrid and private cloud environments. For more insights into the private/hybrid cloud and data center services challenges that enterprises in the U.K. face, plus ISG's advice for overcoming them, see the ISG Provider Lens ® Focal Points briefing here. The 2025 ISG Provider Lens ® Private/Hybrid Cloud — Data Center Services report for the U.K. evaluates the capabilities of 69 providers across five quadrants: Managed Services — Large Accounts, Managed Services — Midmarket, Managed Hosting, Colocation Services and AI-Ready Infrastructure Consulting. The report names Fujitsu and Kyndryl as Leaders in three quadrants each. It names Accenture, Capgemini, Claranet, DXC Technology, Ensono, Hexaware, Infosys, Pulsant, Rackspace Technology, T-Systems and TCS as Leaders in two quadrants each. Atos, Computacenter, Deloitte, Digital Realty, Equinix, Global Switch, HCLTech, IBM, LTIMindtree, NTT DATA, Redcentric, Telefonica Tech, Telehouse, Unisys and Wipro are named as Leaders in one quadrant each. In addition, LTIMindtree, Mphasis and NTT DATA are named as Rising Stars — companies with a 'promising portfolio' and 'high future potential' by ISG's definition — in one quadrant each. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among private/hybrid cloud and data center service providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. Customized versions of the report are available from Hexaware and Unisys. The 2025 ISG Provider Lens ® Private/Hybrid Cloud — Data Center Services report for the U.K. is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens ® Research The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
New York Times
13 minutes ago
- New York Times
F.D.A. Panel to Reassess Hormone Therapy Warnings
Dr. Marty Makary, commissioner of the Food and Drug Administration, will convene an expert panel on Thursday that he said will 'set the record straight' about hormone therapy for menopause, a treatment that he champions despite mixed findings about its risks and benefits. Although there is no public agenda, the panel is expected to discuss whether the risks have been overstated, deterring women who might benefit. All menopause treatments containing the hormone estrogen carry a black box warning that the medication should not be used to prevent cardiovascular disease or dementia, and that it increases the risk of strokes, blood clots and probable dementia. The label also warns of the possibility of breast cancer. But proponents like Dr. Makary say there's evidence that hormone therapy — approved for the treatment of symptoms like hot flashes — may prevent cognitive decline, heart disease and some cancers, in addition to conferring benefits that are not in dispute, like reducing osteoporosis-related fractures. Dr. Makary has dismissed findings of a heightened risk of breast cancer in women who took combined estrogen and progestin, saying the research caused a 'breast cancer scare' that has deterred women from getting a useful treatment. 'There's probably no medication that improves the health outcomes of a population more than hormone replacement therapy for women who start it within 10 years of the onset of menopause,' except perhaps antibiotics, Dr. Makary said on a podcast. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Stifel Downgrades CoreWeave, Inc. (CRWV) To Hold Following Core Scientific Acquisition
CoreWeave, Inc. (NASDAQ:CRWV) is among the 13 Best Booming Stocks to Buy Now. On July 8, Stifel downgraded the stock to Hold from Buy, while lifting its price target to $115 per share from $75. A man in black suit holding a tablet looks at stock market data on a monitor. Photo by Tima Miroshnichenko on Pexels The adjustment followed a recent announcement by the data center infrastructure provider regarding its acquisition of Core Scientific. CoreWeave, Inc. (NASDAQ:CRWV) expects the move to enhance operational efficiencies, improve financial flexibility, and result in expanded expertise. While the analysts acknowledged the likely long-term benefits from the takeover, they noted 'key near-term overhangs', which prompted the firm's cautious outlook for CoreWeave, Inc. (NASDAQ:CRWV) and became the reason for the downgrade. Despite near-term challenges the company could face during the integration phase, Stifel significantly lifted CoreWeave, Inc. (NASDAQ:CRWV)'s price target, reflecting the scale of value creation from the acquisition. CoreWeave, Inc. (NASDAQ:CRWV) is a cloud infrastructure technology company. The stock has had impressive returns of nearly 283% since its IPO in March this year. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None.
